Teriparatide Cuts Spinal Fracture Risk by 70% in Postmenopausal Osteoporosis: Meta-Analysis
A meta-analysis of 8 trials found teriparatide increased spinal bone density by 8% and reduced vertebral fracture risk by 70% in postmenopausal women, with better results when calcium intake exceeded 1,500 mg daily.
Quick Facts
What This Study Found
Teriparatide increased spine bone mineral density by 8.14% and hip BMD by 2.48% in postmenopausal women with osteoporosis. It reduced vertebral fracture risk by 70% (risk ratio 0.30) and non-vertebral fracture risk by 38% (risk ratio 0.62). Women who took more than 1,500 mg of calcium daily had significantly greater hip BMD gains (3.72% vs. 1.40%, p=0.004). Longer treatment duration did not appear to produce additional benefits.
Key Numbers
How They Did This
The researchers searched electronic databases and reference lists, identifying 8 randomized controlled trials with a combined 2,388 postmenopausal women with osteoporosis. All trials evaluated daily subcutaneous teriparatide injections. Data were pooled using a random-effects model, measuring percentage change in bone mineral density and fracture risk ratios.
Why This Research Matters
Osteoporosis fractures cause enormous suffering and healthcare costs in postmenopausal women. This meta-analysis pooled data from 8 randomized controlled trials to confirm that teriparatide — a peptide fragment of parathyroid hormone — is highly effective at building bone and preventing fractures. The finding about calcium intake is practically important: adequate calcium supplementation significantly amplifies teriparatide's effect on hip bone density.
The Bigger Picture
Most osteoporosis drugs (like bisphosphonates) slow bone loss. Teriparatide is different — it's one of the few treatments that actually builds new bone. This meta-analysis provided strong pooled evidence supporting its use, which helped establish teriparatide as a go-to option for women at high fracture risk. The calcium finding also changed clinical practice, emphasizing that adequate calcium intake is essential to getting the full benefit.
What This Study Doesn't Tell Us
Only 3 of the 8 trials reported fracture outcomes, limiting the fracture risk analysis. The meta-analysis included trials of varying duration and calcium supplementation protocols. Publication bias is possible. The analysis could not fully control for differences in study populations across trials.
Questions This Raises
- ?Why doesn't longer teriparatide treatment produce additional gains, and what happens to bone density after stopping?
- ?How does teriparatide compare to newer bone-building agents like abaloparatide and romosozumab?
- ?Is there a minimum calcium intake threshold below which teriparatide becomes significantly less effective?
Trust & Context
- Key Stat:
- 70% fracture reduction Teriparatide reduced vertebral fracture risk by 70% compared to control in postmenopausal women with osteoporosis
- Evidence Grade:
- This is a meta-analysis of 8 randomized controlled trials — one of the strongest forms of clinical evidence. The large combined sample and consistent results support high confidence in the findings.
- Study Age:
- Published in 2012. Teriparatide remains widely used, and these findings have been reinforced by subsequent research. Newer competitors like abaloparatide and romosozumab have since entered the market.
- Original Title:
- Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials.
- Published In:
- International journal of clinical practice, 66(2), 199-209 (2012)
- Database ID:
- RPEP-01953
Evidence Hierarchy
Frequently Asked Questions
How much does teriparatide increase bone density?
This meta-analysis found an average 8.14% increase in spine bone density and 2.48% increase at the hip. Women taking more than 1,500 mg of calcium daily saw hip gains nearly triple those with lower calcium intake.
How effective is teriparatide at preventing fractures?
Very effective — the pooled data showed a 70% reduction in vertebral (spinal) fractures and a 38% reduction in non-vertebral fractures compared to control groups.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01953APA
Han, S-L; Wan, S-L. (2012). Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials.. International journal of clinical practice, 66(2), 199-209. https://doi.org/10.1111/j.1742-1241.2011.02837.x
MLA
Han, S-L, et al. "Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials.." International journal of clinical practice, 2012. https://doi.org/10.1111/j.1742-1241.2011.02837.x
RethinkPeptides
RethinkPeptides Research Database. "Effect of teriparatide on bone mineral density and fracture ..." RPEP-01953. Retrieved from https://rethinkpeptides.com/research/han-2012-effect-of-teriparatide-on
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.